Humam Farah, MD
Pulmonary Disease · Hannibal, MONPI 1306880141
Payments from drug & device makers
Across 1,835 payments — averaging $1494.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$689K
- Genentech, Inc.$493K
- Takeda Pharmaceuticals U.S.A., Inc.$384K
- AstraZeneca$273K
- Sanofi US Services Inc.$179K
- United Therapeutics Corporation$148K
- plus $577K from 47 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$150
What the payments were for
- Consulting fees$17,1882%
- Speaking & faculty fees$686,74582%
- Travel & lodging$106,60513%
- Food & beverage$29,2313%
- Education$3450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLASSIA$442,222
- BREZTRI$185,199
- Ohtuvayre$76,307
- Wakix$43,382
- Yupelri$19,972
- Prolastin-C Liquid$9,870
- BREZTRI AEROSPHERE$6,175
- ARALAST$5,353
- FASENRA$1,860
- Adempas$250
- PT100US/myAIRVO 2$173
- PT101US/AIRVO2$173
- OPT944/Optiflow Nasal Cannula Medium 20Pack$173
- OPT970/Optiflow Tracheostomy interface 20pack$173
- 900PT561/Air Spiral Breathing Tube Chamber kit$173
- Gamunex-C$140
- UPTRAVI$125
- OPSUMIT$125
- TYVASO$110
- LONHALA MAGNAIR$106
How this compares
$2,742,247 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 109 | $1,644,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 1,220 | $923,560 |
| GlassiaAlpha-1-Proteinase Inhibitor | 69 | $857,972 |
| OfevNintedanib Esylate | 63 | $772,185 |
| OpsumitMacitentan | 53 | $651,530 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 36 | $637,354 |
| UptraviSelexipag | 19 | $485,687 |
| Ambrisentan | 71 | $188,281 |
| AdempasRiociguat | 12 | $154,602 |
| Pirfenidone | 44 | $145,554 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $142,528 |
| Spiriva RespimatTiotropium Bromide | 233 | $140,897 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $89,528 |
| TezspireTezepelumab-Ekko | 16 | $72,885 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 131 | $68,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $44,914 | $1,644,872109 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $345 | $1,137,21772 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $272,691 | $1,037,7341,367 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $13,536 | $1,020,688495 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $384,025 | $857,97269 claims |
| CSL BehringHizentra, Privigen | $110,982 | $232,05626 claims |
| BayerAdempas | $317 | $154,60212 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arexvy | $245 | $141,711256 claims |
| PfizerEliquis | $65 | $35,27541 claims |
| MerckDulera | $56,356 | $6,40817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Hannibal
- Jennifer MinoffHannibal$41K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.